Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Similarity of Sintilimab Before and After Manufacturing Change
NCT05337267Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Apr 2022
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised trial of sintilimab in classical Hodgkin lymphoma (cHL), non-small cell lung cancer (NSCLC), Esophageal Squamous Cell Carcinoma (ESCC) and 2 more (2 arms), sponsored by Innovent Biologics. Primary endpoints: Treatment-emergent Adverse Events at Day 43, Serious Adverse Events at Day 43 and 2 more. Started Apr 2022; status: completed.
02
Drugs
sintilimab
03
Conditions
classical Hodgkin lymphoma (cHL)non-small cell lung cancer (NSCLC)Esophageal Squamous Cell Carcinoma (ESCC)gastric cancer (GC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05337267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05337267.